AVTX
AVTX clinical trials: Avalo Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Avalo Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 22
- Trials linked
- 22
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
AVTX on the catalyst calendar · AVTX registry changes
- Primary completion Feb 23, 2026ActualPhase 2NCT06603077A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis SuppurativaAvalo Therapeutics, Inc. · Hidradenitis SuppurativaCompletedAVTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2015ActualPhase 1NCT02286817Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents...Aevi Genomic Medicine, LLC, a Cerecor company · Attention-deficit Hyperactivity Disorder (ADHD)CompletedAVTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 11, 2023ActualPhase 2NCT05288504A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.Avalo Therapeutics, Inc. · Non-Eosinophilic AsthmaCompletedAVTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 30, 2022ActualPhase 1NCT04671251Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple MyelomaAvalo Therapeutics, Inc. · Multiple MyelomaCompletedAVTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 14, 2021ActualPhase 1NCT03169894Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative...Avalo Therapeutics, Inc. · Crohn DiseaseTerminatedAVTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 13, 2017ActualPhase 1NCT02895906Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric ConditionsAevi Genomic Medicine, LLC, a Cerecor company · 22q11.2 Deletion SyndromeCompletedAVTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2016ActualPhase 2NCT02468414TARGTEPO Treatment for Anemia in PD US TrialAevi Genomic Medicine, LLC, a Cerecor company · Anemia of End Stage Renal DiseaseTerminatedAVTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 14, 2020ActualPhase 2NCT04412057Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung InjuryAevi Genomic Medicine, LLC, a Cerecor company · COVID-19 PneumoniaCompletedAVTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2022Sponsor estimatePhase 1NCT04994002A Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults With Complex Lymphatic MalformationsAvalo Therapeutics, Inc. · Lymphatic MalformationWithdrawnAVTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 10, 2017ActualPhase 2/Phase 3NCT02777931Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHDAevi Genomic Medicine, LLC, a Cerecor company · Attention Deficit Disorder With HyperactivityCompletedAVTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 23, 2018ActualPhase 2NCT03609619PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR MutationsAevi Genomic Medicine, LLC, a Cerecor company · Attention Deficit Hyperactivity DisorderCompletedAVTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 24, 2018ActualPhase 2NCT03265119PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR MutationsAevi Genomic Medicine, LLC, a Cerecor company · Attention Deficit Hyperactivity DisorderCompletedAVTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 3, 2018ActualNo phase registeredNCT03233867A Non-interventional Study to Identify Children and Adolescents With ADHD and With or Without mGLuR MutationsAevi Genomic Medicine, LLC, a Cerecor company · Attention Deficit Hyperactivity DisorderCompletedAVTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 26, 2017ActualPhase 1NCT03006367Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHDAevi Genomic Medicine, LLC, a Cerecor company · Attention Deficit Disorder With HyperactivityCompletedAVTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 6, 2017ActualNo phase registeredNCT02811211A Noninterventional Genotype/Phenotype Study of mGluR Mutations in Children and Adolescents With ADHDAevi Genomic Medicine, LLC, a Cerecor company · Attention Deficit Disorder With HyperactivityCompletedAVTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2016ActualPhase 1/Phase 2NCT02117427TARGTEPO Treatment for Anemia in Chronic Kidney Disease (CKD) Patients and End-Stage Renal Disease (ESRD)Aevi Genomic Medicine, LLC, a Cerecor company · Chronic Kidney DiseaseCompletedAVTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2014ActualPhase 2NCT01941043A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With...Avalo Therapeutics, Inc. · Major Depressive DisorderCompletedAVTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2016ActualPhase 2NCT02378662TARGTEPO Treatment for Anemia in End Stage Renal Disease (ESRD) Patients Undergoing Peritoneal Dialysis (PD)Aevi Genomic Medicine, LLC, a Cerecor company · Anemia of End Stage Renal DiseaseTerminatedAVTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2016ActualPhase 2NCT02459236A Study of Intermittent Doses of CERC-301 in MDDAvalo Therapeutics, Inc. · Major Depressive DisorderCompletedAVTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2013ActualPhase 2NCT01703923An Exploratory Study of FP01 Lozenges in Subjects With Chronic Refractory CoughAvalo Therapeutics, Inc. · Chronic Refractory CoughCompletedAVTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2012ActualPhase 2NCT01597349Antitussive Effects of FP01 Lozenges in Subjects With Cough Due to Upper Respiratory Tract InfectionAvalo Therapeutics, Inc. · Acute CoughCompletedAVTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2012ActualPhase 1NCT01579526A Single Dose Study to Determine the Safety and Pharmacokinetics of FP01 Lozenges in Healthy VolunteersAvalo Therapeutics, Inc. · HealthyCompletedAVTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 22 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner